The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established in 2015 to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
The BBCIC is a non-profit, scientific public service initiative that will monitor biosimilars and corresponding novel biologics for effectiveness and safety – to provide the reassurance that patients and physicians want. The BBCIC:
- Is the only research network dedicated to monitoring biosimilars
- Draws on large sets of de-identified medical and pharmacy data (100 million lives)
- Harnesses cutting-edge distributed research network and surveillance methods
Managed care and integrated delivery organizations have devoted significant resources to develop an infrastructure that makes possible active surveillance of biosimilars and novel in distributed research networks (DRNs). The BBCIC marshals these resources for the important public health benefit inherit in monitoring biosimilar safety and effectiveness, using ongoing sequential analyses to compare biosimilars to their innovator product.
The BBCIC mission is to provide a range of research services that support the following value propositions:
- Address important questions about the use, impact, safety, and clinical effectiveness of biologics and biosimilars on human health.
- Increase the rigor and credibility of real world evidence
- Provide access to a large population for epidemiologic studies and health services research
- Improve the efficiency and cost-effectiveness of post-marketed observational studies
- Develop standard approaches to common data needs and address gaps in tools and methods.